tetano
Editor, Senior Moderator
J Clin Lab Anal
. 2022 Apr 14;e24418.
doi: 10.1002/jcla.24418. Online ahead of print.
An overview on inactivated and live-attenuated SARS-CoV-2 vaccines
Saeed Khoshnood[SUP] 1 [/SUP], Maniya Arshadi[SUP] 2 3 [/SUP], Sousan Akrami[SUP] 2 4 [/SUP], Maryam Koupaei[SUP] 5 [/SUP], Hossein Ghahramanpour[SUP] 6 [/SUP], Aref Shariati[SUP] 7 [/SUP], Nourkhoda Sadeghifard[SUP] 1 [/SUP], Mohsen Heidary[SUP] 8 9 [/SUP]
Affiliations
Abstract
After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID-19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID-19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS-CoV-2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS-CoV-2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.
Keywords: COVID-19; SARS-CoV-2; attenuated vaccine; inactivated vaccine; review.
. 2022 Apr 14;e24418.
doi: 10.1002/jcla.24418. Online ahead of print.
An overview on inactivated and live-attenuated SARS-CoV-2 vaccines
Saeed Khoshnood[SUP] 1 [/SUP], Maniya Arshadi[SUP] 2 3 [/SUP], Sousan Akrami[SUP] 2 4 [/SUP], Maryam Koupaei[SUP] 5 [/SUP], Hossein Ghahramanpour[SUP] 6 [/SUP], Aref Shariati[SUP] 7 [/SUP], Nourkhoda Sadeghifard[SUP] 1 [/SUP], Mohsen Heidary[SUP] 8 9 [/SUP]
Affiliations
- PMID: 35421266
- DOI: 10.1002/jcla.24418
Abstract
After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID-19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID-19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS-CoV-2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS-CoV-2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.
Keywords: COVID-19; SARS-CoV-2; attenuated vaccine; inactivated vaccine; review.